Cogentix Medical, Inc. (CGNT) Earns Outperform Rating from Analysts at JMP Securities

JMP Securities began coverage on shares of Cogentix Medical, Inc. (NASDAQ:CGNT) in a research report report published on Friday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $5.00 price target on the medical device company’s stock.

Separately, Zacks Investment Research raised Cogentix Medical from a hold rating to a buy rating and set a $2.50 price objective on the stock in a research report on Friday, August 4th.

Shares of Cogentix Medical (CGNT) opened at 3.11 on Friday. The company’s market capitalization is $189.44 million. The stock’s 50 day moving average price is $2.51 and its 200-day moving average price is $1.98. Cogentix Medical has a 1-year low of $1.37 and a 1-year high of $3.26.

Cogentix Medical (NASDAQ:CGNT) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. Cogentix Medical had a negative return on equity of 13.83% and a negative net margin of 35.88%. The company had revenue of $14.06 million for the quarter, compared to analysts’ expectations of $13.90 million. On average, equities analysts predict that Cogentix Medical will post ($0.03) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Cogentix Medical, Inc. (CGNT) Earns Outperform Rating from Analysts at JMP Securities” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/09/cogentix-medical-inc-cgnt-earns-outperform-rating-from-analysts-at-jmp-securities.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Broadfin Capital LLC boosted its position in shares of Cogentix Medical by 45.2% during the second quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock valued at $1,905,000 after buying an additional 340,771 shares during the last quarter. Northern Trust Corp boosted its position in shares of Cogentix Medical by 0.4% during the second quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock valued at $129,000 after buying an additional 326 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Cogentix Medical by 2.3% during the first quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock valued at $1,013,000 after buying an additional 12,459 shares during the last quarter. 12.67% of the stock is currently owned by institutional investors.

Cogentix Medical Company Profile

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTN

Separately, Zacks Investment Research raised Cogentix Medical from a hold rating to a buy rating and set a $2.50 price objective on the stock in a research report on Friday, August 4th.

Shares of Cogentix Medical (CGNT) opened at 3.11 on Friday. The company’s market capitalization is $189.44 million. The stock’s 50 day moving average price is $2.51 and its 200-day moving average price is $1.98. Cogentix Medical has a 1-year low of $1.37 and a 1-year high of $3.26.

Cogentix Medical (NASDAQ:CGNT) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. Cogentix Medical had a negative return on equity of 13.83% and a negative net margin of 35.88%. The company had revenue of $14.06 million for the quarter, compared to analysts’ expectations of $13.90 million. On average, equities analysts predict that Cogentix Medical will post ($0.03) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Cogentix Medical, Inc. (CGNT) Earns Outperform Rating from Analysts at JMP Securities” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/09/cogentix-medical-inc-cgnt-earns-outperform-rating-from-analysts-at-jmp-securities.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Broadfin Capital LLC boosted its position in shares of Cogentix Medical by 45.2% during the second quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock valued at $1,905,000 after buying an additional 340,771 shares during the last quarter. Northern Trust Corp boosted its position in shares of Cogentix Medical by 0.4% during the second quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock valued at $129,000 after buying an additional 326 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Cogentix Medical by 2.3% during the first quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock valued at $1,013,000 after buying an additional 12,459 shares during the last quarter. 12.67% of the stock is currently owned by institutional investors.

Cogentix Medical Company Profile

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply